was read the article
array:21 [ "pii" => "X2013251413002630" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Nov.11430" "estado" => "S300" "fechaPublicacion" => "2013-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2013;33:85-92" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 8320 "formatos" => array:3 [ "EPUB" => 319 "HTML" => 7254 "PDF" => 747 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699513002633" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2012.Nov.11430" "estado" => "S300" "fechaPublicacion" => "2013-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2013;33:85-92" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 11901 "formatos" => array:3 [ "EPUB" => 328 "HTML" => 10901 "PDF" => 672 ] ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Análisis repetido de la resistencia insulínica estimada mediante índice HOMAIR en pacientes no diabéticos en diálisis peritoneal y su relación con la enfermedad cardiovascular y mortalidad" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "85" "paginaFinal" => "92" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Repeated analysis of estimated insulin resistance using the HOMAIR index in nondiabetic patients on peritoneal dialysis and its relationship with cardiovascular disease and mortality" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11430_108_31956_es_11430_t1.jpg" "Alto" => 250 "Ancho" => 600 "Tamanyo" => 172483 ] ] "descripcion" => array:1 [ "es" => "Características basales de los pacientes en diálisis peritoneal incidentes y prevalentes" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "del Instituto de Salud Carlos III) y del IRSIN Grupo de Estudios Peritoneales de Madrid de REDinREN (Red Renal de investigación de la RETICS 06/0016, del Instituto de Salud Carlos III) y del IRSIN, Rafael Sánchez-Villanueva, Patricia Estrada, Gloria del Peso, Cristina Grande, Juan J. Díez, Pedro Iglesias, Elena González, Ana Aguilar-Rodríguez, Rafael Selgas, M. Auxiliadora Bajo" "autores" => array:11 [ 0 => array:2 [ "nombre" => "del Instituto de Salud Carlos III) y del IRSIN" "apellidos" => "Grupo de Estudios Peritoneales de Madrid de REDinREN (Red Renal de investigación de la RETICS 06/0016, del Instituto de Salud Carlos III) y del IRSIN" ] 1 => array:2 [ "nombre" => "Rafael" "apellidos" => "Sánchez-Villanueva" ] 2 => array:2 [ "nombre" => "Patricia" "apellidos" => "Estrada" ] 3 => array:2 [ "nombre" => "Gloria" "apellidos" => "del Peso" ] 4 => array:2 [ "nombre" => "Cristina" "apellidos" => "Grande" ] 5 => array:2 [ "nombre" => "Juan J." "apellidos" => "Díez" ] 6 => array:2 [ "nombre" => "Pedro" "apellidos" => "Iglesias" ] 7 => array:2 [ "nombre" => "Elena" "apellidos" => "González" ] 8 => array:2 [ "nombre" => "Ana" "apellidos" => "Aguilar-Rodríguez" ] 9 => array:2 [ "nombre" => "Rafael" "apellidos" => "Selgas" ] 10 => array:2 [ "nombre" => "M. Auxiliadora" "apellidos" => "Bajo" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251413002630" "doi" => "10.3265/Nefrologia.pre2012.Nov.11430" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413002630?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513002633?idApp=UINPBA000064" "url" => "/02116995/0000003300000001/v0_201502091331/X0211699513002633/v0_201502091333/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251413002622" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Oct.11560" "estado" => "S300" "fechaPublicacion" => "2013-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2013;33:93-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4780 "formatos" => array:3 [ "EPUB" => 317 "HTML" => 3751 "PDF" => 712 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Advancing in the management of chronic kidney disease: the results of implementing a quick resolution consultation" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "93" "paginaFinal" => "98" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Avanzando en el manejo de la enfermedad renal crónica: resultados de la implantación de una consulta de rápida resolución" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11560_16025_42072_en_t111560i.jpg" "Alto" => 822 "Ancho" => 1071 "Tamanyo" => 235608 ] ] "descripcion" => array:1 [ "en" => "Summary results" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Isidro Torregrosa Maicas, Isidro Torregrosa-Maicas, Isabel Juan García, Isabel Juan-García, Miguel Ángel Solís Salguero, Miguel Á. Solís-Salguero, Carmen Ramos Tomás, Carmen Ramos-Tomás, María Jesús Puchades Montsa, M. Jesús Puchades-Montesa, Miguel González Rico, Miguel González-Rico, Patricia Tomás Simó, Patricia Tomás-Simó, José Ribés Cruz, José Ribés-Cruz, Sandra Tejedor Alonso, Sandra Tejedor-Alonso, Amelia Abarca González, Amelia Abarca-González, Alfonso Miguel Carrasco, Alfonso Miguel-Carrasco" "autores" => array:22 [ 0 => array:2 [ "nombre" => "Isidro" "apellidos" => "Torregrosa Maicas" ] 1 => array:2 [ "nombre" => "Isidro" "apellidos" => "Torregrosa-Maicas" ] 2 => array:2 [ "nombre" => "Isabel" "apellidos" => "Juan García" ] 3 => array:2 [ "nombre" => "Isabel" "apellidos" => "Juan-García" ] 4 => array:2 [ "nombre" => "Miguel Ángel" "apellidos" => "Solís Salguero" ] 5 => array:2 [ "nombre" => "Miguel Á." "apellidos" => "Solís-Salguero" ] 6 => array:2 [ "nombre" => "Carmen" "apellidos" => "Ramos Tomás" ] 7 => array:2 [ "nombre" => "Carmen" "apellidos" => "Ramos-Tomás" ] 8 => array:2 [ "nombre" => "María Jesús" "apellidos" => "Puchades Montsa" ] 9 => array:2 [ "nombre" => "M. Jesús" "apellidos" => "Puchades-Montesa" ] 10 => array:2 [ "nombre" => "Miguel" "apellidos" => "González Rico" ] 11 => array:2 [ "nombre" => "Miguel" "apellidos" => "González-Rico" ] 12 => array:2 [ "nombre" => "Patricia" "apellidos" => "Tomás Simó" ] 13 => array:2 [ "nombre" => "Patricia" "apellidos" => "Tomás-Simó" ] 14 => array:2 [ "nombre" => "José" "apellidos" => "Ribés Cruz" ] 15 => array:2 [ "nombre" => "José" "apellidos" => "Ribés-Cruz" ] 16 => array:2 [ "nombre" => "Sandra" "apellidos" => "Tejedor Alonso" ] 17 => array:2 [ "nombre" => "Sandra" "apellidos" => "Tejedor-Alonso" ] 18 => array:2 [ "nombre" => "Amelia" "apellidos" => "Abarca González" ] 19 => array:2 [ "nombre" => "Amelia" "apellidos" => "Abarca-González" ] 20 => array:2 [ "nombre" => "Alfonso" "apellidos" => "Miguel Carrasco" ] 21 => array:2 [ "nombre" => "Alfonso" "apellidos" => "Miguel-Carrasco" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699513002625" "doi" => "10.3265/Nefrologia.pre2012.Oct.11560" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513002625?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413002622?idApp=UINPBA000064" "url" => "/20132514/0000003300000001/v0_201502091555/X2013251413002622/v0_201502091556/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251413002649" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Sep.11533" "estado" => "S300" "fechaPublicacion" => "2013-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2013;33:77-84" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5146 "formatos" => array:3 [ "EPUB" => 306 "HTML" => 4053 "PDF" => 787 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "77" "paginaFinal" => "84" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento doble con calcifediol asociado a paricalcitol y biomarcadores de riesgo cardiovascular en hemodiálisis" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11533_16025_41491_en_t111533.jpg" "Alto" => 1014 "Ancho" => 2193 "Tamanyo" => 847164 ] ] "descripcion" => array:1 [ "en" => "Modification of the different study variables in both treatment groups over the course of the study" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Celestino Piñera-Haces, María J. Izquierdo-Ortiz, Ángel L. Martín-de Francisco, M. Teresa Garcia-Unzueta, M. Teresa García-Unzueta, Marcos López-Hoyos, Carmen Toyos, Natalia Allende, Estrella Quintela, Manuel Arias" "autores" => array:15 [ 0 => array:2 [ "nombre" => "Celestino" "apellidos" => "Piñera-Haces" ] 1 => array:2 [ "nombre" => "María J." "apellidos" => "Izquierdo-Ortiz" ] 2 => array:2 [ "nombre" => "Ángel L." "apellidos" => "Martín-de Francisco" ] 3 => array:2 [ "nombre" => "Ángel L." "apellidos" => "Martín-de Francisco" ] 4 => array:2 [ "nombre" => "M. Teresa" "apellidos" => "Garcia-Unzueta" ] 5 => array:2 [ "nombre" => "M. Teresa" "apellidos" => "García-Unzueta" ] 6 => array:2 [ "nombre" => "Marcos" "apellidos" => "López-Hoyos" ] 7 => array:2 [ "nombre" => "Marcos" "apellidos" => "López-Hoyos" ] 8 => array:2 [ "nombre" => "Carmen" "apellidos" => "Toyos" ] 9 => array:2 [ "nombre" => "Natalia" "apellidos" => "Allende" ] 10 => array:2 [ "nombre" => "Natalia" "apellidos" => "Allende" ] 11 => array:2 [ "nombre" => "Estrella" "apellidos" => "Quintela" ] 12 => array:2 [ "nombre" => "Estrella" "apellidos" => "Quintela" ] 13 => array:2 [ "nombre" => "Manuel" "apellidos" => "Arias" ] 14 => array:2 [ "nombre" => "Manuel" "apellidos" => "Arias" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699513002641" "doi" => "10.3265/Nefrologia.pre2012.Sep.11533" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513002641?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413002649?idApp=UINPBA000064" "url" => "/20132514/0000003300000001/v0_201502091555/X2013251413002649/v0_201502091556/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "titulo" => "Repeated analysis of estimated insulin resistance using the HOMAIR index in nondiabetic patients on peritoneal dialysis and its relationship with cardiovascular disease and mortality" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "85" "paginaFinal" => "92" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "del Instituto de Salud Carlos III) y del IRSIN Grupo de Estudios Peritoneales de Madrid de REDinREN (Red Renal de investigación de la RETICS 06/0016, del Instituto de Salud Carlos III) y del IRSIN, Rafael Sánchez-Villanueva, Patricia Estrada, Gloria del Peso, Cristina Grande, Juan J. Díez, Pedro Iglesias, Elena González, Ana Aguilar-Rodríguez, Rafael Selgas, M. Auxiliadora Bajo" "autores" => array:11 [ 0 => array:2 [ "nombre" => "del Instituto de Salud Carlos III) y del IRSIN" "apellidos" => "Grupo de Estudios Peritoneales de Madrid de REDinREN (Red Renal de investigación de la RETICS 06/0016, del Instituto de Salud Carlos III) y del IRSIN" ] 1 => array:4 [ "nombre" => "Rafael" "apellidos" => "Sánchez-Villanueva" "email" => array:1 [ 0 => "rjsanchez.hulp@salud.madrid.org" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 2 => array:3 [ "nombre" => "Patricia" "apellidos" => "Estrada" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 3 => array:3 [ "nombre" => "Gloria" "apellidos" => "del Peso" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 4 => array:3 [ "nombre" => "Cristina" "apellidos" => "Grande" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] ] ] 5 => array:3 [ "nombre" => "Juan J." "apellidos" => "Díez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] ] ] 6 => array:3 [ "nombre" => "Pedro" "apellidos" => "Iglesias" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] ] ] 7 => array:3 [ "nombre" => "Elena" "apellidos" => "González" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 8 => array:3 [ "nombre" => "Ana" "apellidos" => "Aguilar-Rodríguez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 9 => array:3 [ "nombre" => "Rafael" "apellidos" => "Selgas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 10 => array:3 [ "nombre" => "M. Auxiliadora" "apellidos" => "Bajo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital Universitario La Paz, Madrid, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] 1 => array:3 [ "entidad" => "Servicio de Bioquímica, Hospital Universitario La Paz, Madrid, " "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] 2 => array:3 [ "entidad" => "Servicio de Endocrinología, Hospital Universitario Ramón y Cajal, Madrid, " "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Análisis repetido de la resistencia insulínica estimada mediante índice HOMAIR en pacientes no diabéticos en diálisis peritoneal y su relación con la enfermedad cardiovascular y mortalidad" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11430_16025_42460_en_t1.11430.jpg" "Alto" => 891 "Ancho" => 2169 "Tamanyo" => 344708 ] ] "descripcion" => array:1 [ "en" => "Baseline characteristics of incident and prevalent patients on peritoneal dialysis" ] ] ] "textoCompleto" => "<p class="elsevierStylePara">Cardiovascular disease (CVD) is the primary cause of death in patients on dialysis.<span class="elsevierStyleSup">1,2</span> The association between peripheral insulin resistance index (IR), hyperinsulinism, and CVD has been explored through numerous cross-sectional and prospective studies.<span class="elsevierStyleSup">1-4 </span>In fact, hyperinsulinism is considered to be a good marker for IR in patients with significant hyperglycaemia. In addition, IR is associated with several risk factors for CVD, such as dyslipidaemia,<span class="elsevierStyleSup">2</span> arterial hypertension,<span class="elsevierStyleSup">5</span> and hypercoagulability.<span class="elsevierStyleSup">2</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Patients with end-stage chronic kidney disease (CKD) develop early IR, characterised by altered carbohydrate metabolism with hyperinsulinemia, which is generally associated with dyslipidaemia and a pro-inflammatory pattern with altered serum levels of adipocytokines.<span class="elsevierStyleSup">6</span> Several studies have demonstrated that IR is possibly associated with a silent and systemic inflammatory process and a micro-inflammatory process characterised by the activation of peripheral cells such as polymorphonuclear cells and monocytes.<span class="elsevierStyleSup">7</span> The final consequence is an elevated rate of atherosclerosis and a high rate of morbidity/mortality due to CVD.<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara"><span class="elsevierStyleSup"> </span></p><p class="elsevierStylePara">Our working hypothesis was based on the possibility that glucose in peritoneal dialysis (PD) solutions could increase IR through an adipocytokine-mediated effect, and contribute to accelerating the process of atherosclerosis in uraemic patients. With this in mind, the objectives of our study included:</p><p class="elsevierStylePara"> </p><li>Evaluate IR in incident and prevalent nondiabetic patients treated with PD.</li><li>Analyse the evolution of IR indices after 1 year of PD treatment.</li><li>Evaluate the effect of IR on subsequent CV morbidity-mortality.</li><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">PATIENTS AND METHOD</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Patients</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Ours was a prospective and observational study involving a cohort of incident and prevalent patients treated with PD. A total of 69 nondiabetic patients on PD were included, 35 of which were incident (≤3 months on PD) and 34 of which were prevalent (>3 months on PD). In addition, 58% were treated with automated peritoneal dialysis, and 42% with continuous ambulatory peritoneal dialysis, with 2 measurements of insulin resistance taken 12 months apart using the homeostasis model assessment insulin resistance (HOMAIR). The purpose of this combined evaluation was to test the reproducibility, potential changes derived from PD, and the influence of these parameters on the appearance of CV events and mortality.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">We excluded patients with active forms of cancer, acute infections, uncontrolled or systemic chronic inflammatory disease, or an initial glycaemia value >140mg/dl.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">The causes of kidney disease were glomerulonephritis in 21 patients (30.4%), nephroangiosclerosis/vascular in 8 patients (11.6%), other causes in 8 patients (11.6%), polycystic kidney disease in 7 patients (10.1%), systemic disease in 7 patients (10.1%), unknown in 7 patients (10.1%), chronic pyelonephritis in 5 patients (7.2%), interstitial nephropathy in 5 patients (7.2%), and hereditary in 1 patient (1.4%).</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">At the time of the first measurement of IR, we considered baseline and start of follow-up times for the survival analysis.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Comorbidity was evaluated using the Charlson index as modified by Beddhu.<span class="elsevierStyleSup">9</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">LABORATORY PROCEDURES</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Laboratory parameters were measured at baseline values and after 1 year of evolution, always following 12 hours of fast and maintaining normal regimens of PD treatment. We also compiled dialysis parameters, such as Kt/V from weekly urine samples and normalised protein nitrogen appearance (nPNA).</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Insulin was measured using a double enzyme immunometric assay method with an AIA 360 auto-analyser (Tosoh Bioscience). The inter and intra-trial coefficients of variation were 1.7% and 3.3%, respectively. The sensitivity of the analysis was 1µU/ml. The normal range for insulin levels in our laboratory was 2-17µU/ml.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Based on baseline insulinemia and glycaemia values, we calculated HOMAIR index scores based on the formula by Matthews et al.<span class="elsevierStyleSup">10</span>: HOMAIR = glucose (mmol/l) x insulin (µU/ml)/22.5. We also calculated the quantitative insulin sensitivity check index based on the protocol by Hrebicek et al.<span class="elsevierStyleSup">11</span>: QUICKI = 1/[log fasting insulin level (mU/l) – log fasting glycaemia (mg/dl)].</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Definitions</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Coronary disease:</span> a history of angina, myocardial infarction, coronary angiography evidence, percutaneous intervention, or coronary bypass.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Congestive heart failure:</span> New York Heart Association (NYHA) classification<span class="elsevierStyleSup">12</span>:</p><p class="elsevierStylePara">- Functional class I: normal activity with no symptoms. No limitations to physical activity.</p><p class="elsevierStylePara">- Functional class II: the patient tolerates normal activity, but physical activity is slightly limited due to dyspnoea that appears during intense exercise.</p><p class="elsevierStylePara">- Functional class III: the patient’s capacity for physical activity is lower than normal, with notable limitations due to dyspnoea.</p><p class="elsevierStylePara">- Functional class IV: the patient suffers dyspnoea upon the slightest effort or even at rest, and is incapable of performing virtually any physical activity</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Peripheral arterial disease:</span> patients with intermittent claudication, arterial <span class="elsevierStyleItalic">bypass</span>, amputation, gangrene, acute arterial insufficiency, or unrepaired aneurysms of the thoracic or abdominal arteries greater than 5cm.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Cerebral vascular disease:</span> patients with a history of cerebrovascular accidents or transitory ischaemic accidents (with mild or zero sequelae).</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Dyslipidemia: </span>one or more of the following criteria<span class="elsevierStyleSup">13</span>: 1) LDL (low-density lipoprotein) cholesterol ≥100mg/dl; 2) non-HDL (non-high-density lipoprotein) cholesterol ≥130mg/dl; 3) triglycerides ≥150mg/dl; 4) HDL cholesterol ≤40mg/dl; and 5) the use of one or more lipid-lowering drugs.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Hypertension:</span> blood pressure (BP) was measured using a digital monitor (HEM-907) with cuffs adapted to the circumference of each patient’s arm, once the patient had been laying at rest for at least 5 minutes. Hypertension was diagnosed when the patient fulfilled one or more of the following criteria<span class="elsevierStyleSup">14</span>: 1) systolic BP≥135mm Hg; 2) diastolic BP≥85mm Hg; and 3) the use of one or more anti-hypertensive drugs.</p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">STATISTICAL ANALYSIS</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Values were expressed as means (± standard deviation) and percentages. Proportions were compared using chi-square tests, and means were compared using Student’s t-tests for variables with a normal distribution, and Mann-Whitney or Wilcoxon tests were used for non-parametric quantitative variables. We performed a linear regression analysis using Pearson and Spearman correlation coefficients. We used the Kaplan-Meier method for the survival analysis, and compared curves using the log-rank method. A <span class="elsevierStyleItalic">P</span>-value <.05 was considered to be statistically significant for all cases.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Table 1 summarises the baseline clinical characteristics for the two patient groups, classified based on prior time on PD (incident and prevalent patients). We did not observe significant differences between the two groups.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">The mean time on PD was 32.1±16.0 months (range: 11-87 months).</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Table 2 displays the mean dialysis parameters, laboratory values, and insulin resistance indices (HOMAIR and QUICKI) at initial evaluations and after 12 months of follow-up. We only observed statistically significant differences between the two groups in the fields of residual renal function, total cholesterol, and LDL cholesterol.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">At the start of treatment, 60% of incident patients were on treatment with icodextrin, as compared to 57.1% after 12 months. In prevalent patients, the rate of use of icodextrin was 73.5% at both evaluations.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">HOMAIR and initial insulin levels</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">When patients were classified based on median initial HOMAIR score (HOMAIR: 1.7; range: 6.29), we observed that incident patients with higher HOMAIR scores had significantly higher levels of total calcium and ionised calcium as compared to patients with lower HOMAIR scores. In prevalent patients, we did not observe significant differences for this parameter (Table 3). Upon classifying patients based on median insulinemia (7.0; range: 2-25), the findings were similar.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">We did not observe differences in HOMAIR or QUICKI scores based on the different concentrations of glucose in peritoneal dialysate solutions, both at the start of the study and after 1 year (data not shown).</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Comorbidity analysis</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">When we analysed patients based on the median value for baseline HOMAIR score, we did not observe statistically significant differences for CV comorbidity, ischaemic heart disease, heart failure, or cerebral/peripheral vascular comorbidity. We encountered the same result when separating patients based on the median value for initial insulin.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">We did not observe a significant difference between patients with HOMAIR scores above and below the median value in terms of Charlson comorbidity score (with age excluded) (3.2±1.6 vs. 3.4±1.3).</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">The presence of CVD did not significantly affect HOMAIR scores.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Survival analysis</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Eighteen patients (26%) died during the follow-up period, with death of vascular origin being the most common source of mortality (n=5; 27.8%), followed by cardiac causes (n=4; 22.2%), infectious causes (n=4; 22.2%), deterioration (n=2; 11.1%), tumours (n=1.5; 6%) and other (n=2; 11.1%).</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Survival analysis revealed that patients who died were mostly male (11 vs 7; <span class="elsevierStyleItalic">P</span>=.001), elderly (63.6±12.3 vs 45.7±16.8 years of age; <span class="elsevierStyleItalic">P</span>=.000), and a higher Charlson index score (with age excluded) (4.5±1.1 vs 2.9±1.3; <span class="elsevierStyleItalic">P</span>=.000). We did not observe statistically significant differences in terms of IR index values (data not shown).</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">The global Kaplan-Meier survival analysis did not reveal significant differences in terms of mortality between patients with HOMAIR index scores above and below the median value (Figure). In a similar manner, we did not observe differences in terms of CV mortality and fatal/non-fatal CV events during the study (data not shown).</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">In this study, we analysed the effects of PD on parameters of insulin resistance (HOMAIR and QUICKI) and the influence of these scores on the appearance of CV events and mortality in a group of nondiabetic PD patients.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">IR is very common among uraemic patients, occurring even in early phases.<span class="elsevierStyleSup">15</span> Several different hypotheses have been proposed in an attempt to explain IR: 1) hyper-production of endogenous proinflammatory factors such as homocysteine,<span class="elsevierStyleSup">16</span> oxidative stress,<span class="elsevierStyleSup">17</span> and elevated lipoprotein (a) levels,<span class="elsevierStyleSup">18</span> and exogenous proinflammatory factors such as chronic infections (sometimes silent) by <span class="elsevierStyleItalic">Helicobacter pylori</span>,<span class="elsevierStyleSup">19</span> infected vascular prostheses, or intravenous iron administration, among others<span class="elsevierStyleSup">20</span>; and 2) increased adipose tissue<span class="elsevierStyleSup">21</span> due to excess caloric intake, which leads to a vicious circle with increased production of adipocytokines (leptin, resistin) and other proinflammatory mediators such as nuclear factor kappa beta, tumour necrosis factor alpha, and interleukin 6.<span class="elsevierStyleSup">22</span> These chemokines act as chemotactic proteins for monocytes and macrophages (MCP-1),<span class="elsevierStyleSup">23,24</span> thus perpetuating IR.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">In patients on PD, the development of IR is attributed to the excessive amount of glucose absorbed through dialysate fluids, which contributes to other metabolic disorders such as central obesity, hypertriglyceridemia, and <span class="elsevierStyleItalic">de novo</span> diabetes.<span class="elsevierStyleSup">25</span> This process also induces hyper-secretion of adipocytokines, which perpetuate hyperinsulinism and its deleterious metabolic and systemic effects. According to the study by Fortes et al.,<span class="elsevierStyleSup">26</span> patients on PD have higher fasting glucose levels, HbA<span class="elsevierStyleInf">1c</span>, and HOMAIR index scores than patients on haemodialysis. Also, patients who receive dialysis with glucose-free dialysate exhibit a lower absorption of glucose, lower weight gain and fat accumulation, reduced levels of plasma leptin and increased levels of plasma adiponectin, and improved IR and dyslipidemia.<span class="elsevierStyleSup">27,28</span> In our study, mean glucose, insulin, and IR (as measured by HOMAIR and QUICKI indices) levels were similar between initial measurements and after 1 year in both incident and prevalent patients.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Bonora et al.<span class="elsevierStyleSup">29</span> examined a large sample of patients with type 2 diabetes, and showed that IR (as estimated using the HOMAIR index) was a strong predictor for CVD, both at the start of the study and during follow-up. This correlation was independent of traditional CV factors and variables closely related to IR, such as body mass index. Also, despite the fact that several studies have shown that hyperinsulinemia is capable of predicting CVD,<span class="elsevierStyleSup">4,30</span> others, in contrast, have not found a significant association between plasma insulin levels and CVD.<span class="elsevierStyleSup">31</span> In our study, we did not observe significant differences in terms of CV comorbidity, ischaemic heart disease, heart failure, or cerebral vascular comorbidity based on HOMAIR index scores or insulin levels. The Charlson index score (without the factor of age included) was also similar among all patients. Nor did we observe a relationship between the presence of prior CVD and HOMAIR scores.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Glucose in PD solutions may have an effect on abdominal adipocytes, which, through an increase in the secretion of adipocytokines, may increase IR, thus favouring the development of metabolic syndromes and accelerating the process of atherosclerosis in uremic patients. Upon analysis of our results, we did not observe significant differences in HOMAIR or QUICKI index scores based on the concentrations of glucose used in PD solutions.</p><p class="elsevierStylePara">In the general population, IR is considered to be a factor for CV risk and mortality,<span class="elsevierStyleSup">32,33</span> whereas this factor appears to have a different significance in studies carried out with CKD patients. A study by Shinohara et al.<span class="elsevierStyleSup">34</span> demonstrated that HOMAIR scores predicted mortality in nondiabetic patients with CKD. However, other studies have not observed this relationship.<span class="elsevierStyleSup">35</span> In our survival analysis, we did not observe statistically significant differences in terms of IR scores or when classifying patients based on median HOMAIR values in a Kaplan-Meier analysis. It may be that other characteristics of these patients, such as age or comorbidity, may play a greater role in determining survival than insulin resistance. In addition, the HOMAIR scores recorded in our study fell within normal limits, which would also impede the possibility of significant differences in terms of survival.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Bonora et al.<span class="elsevierStyleSup">36</span> observed mean HOMAIR values of 2.06±0.14 in a population of 62 healthy individuals using a double-antibody radioimmunoassay for measuring plasma insulin. In a study involving 490 nondiabetic volunteers, 77% of which were Caucasian, of both sexes, aged 19-79 years, and with a body mass index of 18-42.2, the researchers observed a mean HOMAIR score of 2.7±.1.<span class="elsevierStyleSup">37</span> The mean HOMAIR value in normal individuals (with no glucose metabolism disorders) from a study prior to ours was 2.22±0.26.<span class="elsevierStyleSup">38</span> The HOMAIR values recorded in our study, both in incident and prevalent patients, placed between the 50<span class="elsevierStyleSup">th</span> and 75<span class="elsevierStyleSup">th</span> percentile of the values recorded for the general population in Spain according to a recent study.<span class="elsevierStyleSup">39</span> Caravaca et al.<span class="elsevierStyleSup">40</span> observed higher mean HOMAIR values than ours (mean: 4.28±2.07) in a population of nondiabetic patients with CKD. These data support the results obtained in nondiabetic patients on PD, indicating that HOMAIR scores are not significantly elevated in these individuals as compared to the general population, and that this result does not vary over time on dialysis, at least within a period of one year.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">We recognise that our study involves the limitation of only including patients with an initial glycaemia >140mg/dl instead of the cut-off value for diagnosing diabetes in the general population of ≥126mg/dl, but since our study involved patients on PD with a continuous glucose input, we intended to assess a cohort of patients with a baseline glucose level close to normal values, although with the exclusion of diabetic patients. It is possible that, through the use of this more permissive threshold, we may have included patients with less severe disorders of glucose metabolism, such as carbohydrate intolerance, but it was our intention to only exclude patients with clear cases of diabetes. The fact that, in order to be included in our study, all patients needed to have at least one year on PD also implies a bias in our survival analysis. In addition, this study is limited by the small number of patients evaluated, but it does offer a double approach assessing patients at different stages of PD treatment (initial and late), with consistent results across both groups. The prospective approach used also considerably bolsters the results obtained.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">To conclude, nondiabetic patients on PD do not have significantly elevated HOMAIR scores, or modifications to these values after one year of treatment on PF, which suggests that PD is not the cause of increased risk of IR. The fact that IR indices were not associated with CV morbidity/mortality rates appears to suggest that this factor holds little sway in the field of PD.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">The authors declare that they have no conflicts of interest related to the contents of this article.</p><p class="elsevierStylePara"><a href="grande/11430_16025_42460_en_t1.11430.jpg" class="elsevierStyleCrossRefs"><img src="11430_16025_42460_en_t1.11430.jpg" alt="Baseline characteristics of incident and prevalent patients on peritoneal dialysis"></img></a></p><p class="elsevierStylePara">Table 1. Baseline characteristics of incident and prevalent patients on peritoneal dialysis</p><p class="elsevierStylePara"><a href="grande/11430_16025_42461_en_t2.11430.jpg" class="elsevierStyleCrossRefs"><img src="11430_16025_42461_en_t2.11430.jpg" alt="Dialysis parameters, laboratory values, and peripheral insulin resistance indices in patients on peritoneal dialysis; baseline and after 1 year of follow-up"></img></a></p><p class="elsevierStylePara">Table 2. Dialysis parameters, laboratory values, and peripheral insulin resistance indices in patients on peritoneal dialysis; baseline and after 1 year of follow-up</p><p class="elsevierStylePara"><a href="grande/11430_16025_42462_en_t3.11430.jpg" class="elsevierStyleCrossRefs"><img src="11430_16025_42462_en_t3.11430.jpg" alt="Comparison of baseline values for laboratory parameters based on median HOMAIR values (median: 1.7; range: 6-29)"></img></a></p><p class="elsevierStylePara">Table 3. Comparison of baseline values for laboratory parameters based on median HOMAIR values (median: 1.7; range: 6-29)</p><p class="elsevierStylePara"><a href="grande/11430_16025_42463_en_f19.114304.jpg" class="elsevierStyleCrossRefs"><img src="11430_16025_42463_en_f19.114304.jpg" alt="Kaplan-Meier curves, median HOMAIR vs patient death"></img></a></p><p class="elsevierStylePara">Figure 1. Kaplan-Meier curves, median HOMAIR vs patient death</p>" "pdfFichero" => "P1-E547-S3850-A11430-EN.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:7 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec436851" "palabras" => array:1 [ 0 => "Mortalidad" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec436853" "palabras" => array:1 [ 0 => "Índice QUIKI" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec436855" "palabras" => array:1 [ 0 => "Índice HOMA" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec436857" "palabras" => array:1 [ 0 => "Enfermedad cardiovascular" ] ] 4 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec436859" "palabras" => array:1 [ 0 => "Resistencia a la insulina" ] ] 5 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec436861" "palabras" => array:1 [ 0 => "Diálisis peritoneal" ] ] 6 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec436863" "palabras" => array:1 [ 0 => "Enfermedad renal crónica" ] ] ] "en" => array:7 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec436852" "palabras" => array:1 [ 0 => "Mortality" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec436854" "palabras" => array:1 [ 0 => "QUIKI Index" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec436856" "palabras" => array:1 [ 0 => "HOMAIR Index" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec436858" "palabras" => array:1 [ 0 => "Cardiovascular disease" ] ] 4 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec436860" "palabras" => array:1 [ 0 => "Insulin resistance" ] ] 5 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec436862" "palabras" => array:1 [ 0 => "Peritoneal dialysis" ] ] 6 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec436864" "palabras" => array:1 [ 0 => "Chronic kidney disease" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<p class="elsevierStylePara">Los pacientes con enfermedad renal crónica terminal muestran precozmente resistencia insulínica (RI), caracterizada por alteraciones en el metabolismo hidrocarbonado e hiperinsulinemia generalmente asociada a dislipemia y a un patrón pro inflamatorio. La enfermedad cardiovascular (CV) constituye la principal causa de mortalidad en los pacientes en diálisis. Existe una fuerte asociación entre RI, hiperinsulinismo y enfermedad CV. El objetivo del presente estudio fue evaluar el efecto de la diálisis peritoneal (DP) sobre la RI y sus efectos sobre la morbimortalidad CV subsiguiente en pacientes urémicos no diabéticos. Se incluyeron 69 pacientes no diabéticos en DP, 35 incidentes (≤ 3 meses en DP) y 34 prevalentes (> 3 meses en DP), con 2 mediciones de resistencia insulínica estimada mediante el índice de resistencia a la insulina (HOMAIR), separadas entre sí por 12 meses. El valor medio de HOMAIR en pacientes incidentes fue 1,8 ± 1,3 y 2,2 ± 2,1 en situación basal y a los 12 meses, respectivamente (no significativa [ns]). En pacientes prevalentes estos valores fueron 2,3 ± 1,3 y 2,5 ± 2,2 (ns). En nuestro estudio, las concentraciones medias de glucosa, insulina y RI medida por el HOMAIR y QUICKI (índice cuantitativo de control de la sensibilidad a la insulina) fueron similares en situación basal y al año de seguimiento, tanto en incidentes como en prevalentes. No objetivamos diferencias significativas en relación con la comorbilidad CV, cardiopatía isquémica, insuficiencia cardíaca o comorbilidad vascular cerebral o periférica, ni en función del índice HOMAIR, ni en el de los niveles de insulina. En conclusión, los pacientes no diabéticos en DP no presentan elevación significativa de los niveles de HOMAIR, ni se modifica con paso del tiempo en diálisis, lo que sugiere que la DP no es un factor de riesgo de RI. El hecho de que los índices de RI no se asocien a morbilidad o mortalidad CV parece sugerir el menor peso de este factor en el ámbito de la DP.</p>" ] "en" => array:1 [ "resumen" => "<p class="elsevierStylePara">End-stage renal disease patients show early insulin resistance (IR), characterised by alterations in the carbohydrate metabolism and hyperinsulinaemia generally associated with dyslipidaemia and a proinflammatory condition. Cardiovascular disease (CVD) is the main cause of mortality in patients on dialysis. There is a strong association between IR, hyperinsulinism and CV disease. The objective of this study was to evaluate the effect of peritoneal dialysis (PD) on IR and its effects on the subsequent CVD morbidity and mortality in nondiabetic uraemic patients. It involved 69 nondiabetic patients on PD, 35 incident patients (≤ 3 months on PD) and 34 prevalent patients (> 3 months on PD), with 2 estimated insulin resistance measurements 12 months apart using the insulin resistance index (HOMAIR). The mean HOMAIR value in incident patients was 1.8 ± 1.3 and 2.2 ± 2.1 at baseline situation and at 12 months respectively (not significant [NS]). In prevalent patients these values were 2.3 ± 1.3 and 2.5 ± 2.2 (NS). In our study, the mean glucose, insulin and IR concentrations measured by the HOMAIR and QUICKI indexes (the latter being a quantitative control for insulin sensitivity control) were similar at baseline situation and the following year, in both incident and prevalent patients. We did not find any significant differences in relation to CVD comorbidity, ischaemic heart disease, heart failure or cerebrovascular or peripheral comorbidity neither in the HOMAIR index or insulin levels. To conclude, nondiabetic patients on PD do not display a significant increase in HOMAIR levels and this remains the case over time when on dialysis. This, in turn, suggests that PD is not an IR risk factor. The fact that the IR indexes are not associated with CVD morbidity or mortality seems to suggest that this is a less significant factor in the field of PD.</p>" ] ] "multimedia" => array:4 [ 0 => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11430_16025_42460_en_t1.11430.jpg" "Alto" => 891 "Ancho" => 2169 "Tamanyo" => 344708 ] ] "descripcion" => array:1 [ "en" => "Baseline characteristics of incident and prevalent patients on peritoneal dialysis" ] ] 1 => array:8 [ "identificador" => "fig2" "etiqueta" => "Tab. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11430_16025_42461_en_t2.11430.jpg" "Alto" => 812 "Ancho" => 2185 "Tamanyo" => 304807 ] ] "descripcion" => array:1 [ "en" => "Dialysis parameters, laboratory values, and peripheral insulin resistance indices in patients on peritoneal dialysis; baseline and after 1 year of follow-up" ] ] 2 => array:8 [ "identificador" => "fig3" "etiqueta" => "Tab. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11430_16025_42462_en_t3.11430.jpg" "Alto" => 601 "Ancho" => 2144 "Tamanyo" => 263090 ] ] "descripcion" => array:1 [ "en" => "Comparison of baseline values for laboratory parameters based on median HOMAIR values (median: 1.7; range: 6-29)" ] ] 3 => array:8 [ "identificador" => "fig4" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11430_16025_42463_en_f19.114304.jpg" "Alto" => 876 "Ancho" => 1011 "Tamanyo" => 89722 ] ] "descripcion" => array:1 [ "en" => "Kaplan-Meier curves, median HOMAIR vs patient death" ] ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:40 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 2003;16(2):111-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12641874" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Lowrie EG, Lazarus JM, Mocelin AJ, Bailey GL,\u{A0}Hampers CL,\u{A0}Wilson RE,\u{A0}et al. Survival of patients undergoing chronic hemodialysis and renal transplantation. N Engl J Med 1973;288(17):863-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/4571245" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980;19(3):205-10. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6997122" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2(2):154-60. <a href="http://www.ncbi.nlm.nih.gov/pubmed/520119" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334(6):374-81. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8538710" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2005;45(2):275-80. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15685504" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Merino A, Nogueras S, Buendía P, Ojeda R,\u{A0}Carracedo J,\u{A0}Ramirez-Chamond R,\u{A0}et al. Microinflammation and endothelial damage in hemodialysis. Contrib Nephrol 2008;161:83-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18451662" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "García-López E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P. Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int 2007;27 Suppl 2:S205-S209. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17556305" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 2000;108(8):609-13. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10856407" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3899825" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hrebicek J, Janout V, Malincikova J, Horakova D, Cizek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab 2002;87(1):144-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11788638" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hurst JW, Morris DC, Alexander RW. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. Clin Cardiol 1999;22(6):385-90." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157(21):2413-46. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9385294" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A,\u{A0}Prager R,\u{A0}Franek E,\u{A0}et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998;53(5):1343-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9573550" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Gillum R. Distribution of serum total homocysteine and its association with diabetes and cardiovascular risk factors of the insulin resistance syndrome in Mexican American men: the Third National Health and Nutrition Examination Survey. Nutr J 2003;2:6." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001;17(3):189-212. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11424232" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92(1):141-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8325978" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Aguilera A, Gonzalez-Espinoza L, Codoceo R, Jara Mdel C,\u{A0}Pavone M,\u{A0}Bajo MA,\u{A0}et al. Bowel bacterial overgrowth as another cause of malnutrition, inflammation, and atherosclerosis syndrome in peritoneal dialysis patients. Adv Perit Dial 2010;26:130-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21348395" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Amore A, Coppo R. Immunological basis of inflammation in dialysis. Nephrol Dial Transplant 2002;17 Suppl 8:16-24. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12147772" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983;72(3):1150-62. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6350364" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 2003;27 Suppl 3:S49-S52. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14704745" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003;100(12):7265-70. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12756299" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Takahashi K, Mizuarai S, Araki H, Mashiko S,\u{A0}Ishihara A,\u{A0}Kanatani A,\u{A0}et al. Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem 2003;278(47):46654-60. <a href="http://www.ncbi.nlm.nih.gov/pubmed/13129912" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK. New-onset hyperglycemia in nondiabetic chinese patients started on peritoneal dialysis. Am J Kidney Dis 2007;49(4):524-32. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17386320" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Fortes PC, Mendes JG, Riella MC, Pecoits-Filho R.\u{A0}Carbohydrate metabolism disturbances in non-diabetic patients on peritoneal dialysis. Perit Dial Int 2006;26 Suppl 2:Abstract." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Furuya R, Odamaki M, Kumagai H, Hishida A. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 2006;21(2):494-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16221697" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Cho KH, Do JY, Park JW, Yoon KW. Effect of icodextrin dialysis solution on body weight and fat accumulation over time in CAPD patients. Nephrol Dial Transplant 2010;25(2):593-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19767632" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bonora E, Targher G, Alberiche M, Bonadonna RC,\u{A0}Saggiani F,\u{A0}Zenere MB,\u{A0}et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23(1):57-63. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10857969" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Després JP, Lamarche B, Mauriège P, Cantin B,\u{A0}Dagenais GR,\u{A0}Moorjani S,\u{A0}et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334(15):952-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8596596" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hargreaves AD, Logan RL, Elton RA, Buchanan KD, Oliver MF, Riemersma RA. Glucose tolerance, plasma insulin, HDL cholesterol and obesity: 12-year follow-up and development of coronary heart disease in Edinburgh men. Atherosclerosis 1992;94(1):61-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1632860" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000;106(4):453-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10953019" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 32 => array:3 [ "identificador" => "bib33" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86(2):713-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11158035" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 33 => array:3 [ "identificador" => "bib34" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Shinohara K, Shoji T, Emoto M, Tahara H,\u{A0}Koyama H,\u{A0}Ishimura E,\u{A0}et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002;13(7):1894-900. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12089386" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 34 => array:3 [ "identificador" => "bib35" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Becker B, Kronenberg F, Kielstein JT, Haller H,\u{A0}Morath C,\u{A0}Ritz E,\u{A0}et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005;16(4):1091-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15743998" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:1 [ "itemHostRev" => array:3 [ "pii" => "S152586101000126X" "estado" => "S300" "issn" => "15258610" ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib36" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bonora E, Targher G, Alberiche M, Bonadonna RC,\u{A0}Saggiani F,\u{A0}Zenere MB,\u{A0}et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23(1):57-63. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10857969" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 36 => array:3 [ "identificador" => "bib37" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000;23(2):171-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10868826" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 37 => array:3 [ "identificador" => "bib38" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Díez JJ, Grande C, Méndez J, González-Gancedo P, Iglesias P. Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 2006;65(1):27-34." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 38 => array:3 [ "identificador" => "bib39" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, Gude F,\u{A0}Cadarso-Suarez C,\u{A0}García F,\u{A0}et al. Insulin resistance index (HOMA-IR) levels in a general adult population: curves percentile by gender and age. The EPIRCE study. Diabetes Res Clin Pract 2011;94(1):146-55. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21824674" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 39 => array:3 [ "identificador" => "bib40" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Caravaca F, Cerezo I, Macías R, García de Vinuesa E,\u{A0}Martínez del Viejo C,\u{A0}Villa J,\u{A0}et al. [Insulin resistance in chronic kidney disease: its clinical characteristics and prognosis significance]. Nefrologia 2010;30(6):661-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21113216" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003300000001/v0_201502091555/X2013251413002630/v0_201502091556/en/main.assets" "Apartado" => array:4 [ "identificador" => "35441" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Originals" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003300000001/v0_201502091555/X2013251413002630/v0_201502091556/en/P1-E547-S3850-A11430-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413002630?idApp=UINPBA000064" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 9 | 4 | 13 |
2024 October | 69 | 44 | 113 |
2024 September | 74 | 58 | 132 |
2024 August | 76 | 79 | 155 |
2024 July | 68 | 69 | 137 |
2024 June | 82 | 55 | 137 |
2024 May | 104 | 60 | 164 |
2024 April | 58 | 31 | 89 |
2024 March | 55 | 27 | 82 |
2024 February | 69 | 34 | 103 |
2024 January | 74 | 20 | 94 |
2023 December | 78 | 32 | 110 |
2023 November | 74 | 32 | 106 |
2023 October | 104 | 45 | 149 |
2023 September | 83 | 36 | 119 |
2023 August | 72 | 24 | 96 |
2023 July | 97 | 43 | 140 |
2023 June | 59 | 31 | 90 |
2023 May | 60 | 33 | 93 |
2023 April | 66 | 27 | 93 |
2023 March | 68 | 21 | 89 |
2023 February | 49 | 24 | 73 |
2023 January | 54 | 31 | 85 |
2022 December | 86 | 30 | 116 |
2022 November | 85 | 47 | 132 |
2022 October | 85 | 69 | 154 |
2022 September | 67 | 41 | 108 |
2022 August | 72 | 34 | 106 |
2022 July | 54 | 53 | 107 |
2022 June | 70 | 26 | 96 |
2022 May | 68 | 40 | 108 |
2022 April | 118 | 48 | 166 |
2022 March | 113 | 58 | 171 |
2022 February | 117 | 47 | 164 |
2022 January | 137 | 52 | 189 |
2021 December | 96 | 38 | 134 |
2021 November | 89 | 33 | 122 |
2021 October | 74 | 54 | 128 |
2021 September | 78 | 41 | 119 |
2021 August | 73 | 46 | 119 |
2021 July | 83 | 31 | 114 |
2021 June | 55 | 28 | 83 |
2021 May | 87 | 40 | 127 |
2021 April | 136 | 33 | 169 |
2021 March | 89 | 42 | 131 |
2021 February | 108 | 26 | 134 |
2021 January | 64 | 26 | 90 |
2020 December | 84 | 18 | 102 |
2020 November | 73 | 24 | 97 |
2020 October | 63 | 16 | 79 |
2020 September | 49 | 19 | 68 |
2020 August | 101 | 15 | 116 |
2020 July | 108 | 14 | 122 |
2020 June | 99 | 11 | 110 |
2020 May | 83 | 10 | 93 |
2020 April | 68 | 19 | 87 |
2020 March | 87 | 10 | 97 |
2020 February | 93 | 21 | 114 |
2020 January | 116 | 15 | 131 |
2019 December | 149 | 30 | 179 |
2019 November | 125 | 22 | 147 |
2019 October | 100 | 9 | 109 |
2019 September | 125 | 23 | 148 |
2019 August | 88 | 8 | 96 |
2019 July | 107 | 24 | 131 |
2019 June | 92 | 33 | 125 |
2019 May | 94 | 18 | 112 |
2019 April | 111 | 27 | 138 |
2019 March | 66 | 22 | 88 |
2019 February | 42 | 15 | 57 |
2019 January | 56 | 17 | 73 |
2018 December | 193 | 40 | 233 |
2018 November | 147 | 19 | 166 |
2018 October | 161 | 21 | 182 |
2018 September | 276 | 23 | 299 |
2018 August | 178 | 25 | 203 |
2018 July | 126 | 26 | 152 |
2018 June | 117 | 22 | 139 |
2018 May | 126 | 20 | 146 |
2018 April | 123 | 12 | 135 |
2018 March | 78 | 15 | 93 |
2018 February | 64 | 7 | 71 |
2018 January | 71 | 11 | 82 |
2017 December | 88 | 11 | 99 |
2017 November | 93 | 19 | 112 |
2017 October | 74 | 8 | 82 |
2017 September | 61 | 12 | 73 |
2017 August | 69 | 12 | 81 |
2017 July | 69 | 10 | 79 |
2017 June | 85 | 9 | 94 |
2017 May | 121 | 14 | 135 |
2017 April | 79 | 11 | 90 |
2017 March | 99 | 25 | 124 |
2017 February | 131 | 19 | 150 |
2017 January | 72 | 16 | 88 |
2016 December | 77 | 6 | 83 |
2016 November | 127 | 14 | 141 |
2016 October | 183 | 14 | 197 |
2016 September | 315 | 9 | 324 |
2016 August | 474 | 8 | 482 |
2016 July | 282 | 13 | 295 |
2016 June | 198 | 0 | 198 |
2016 May | 178 | 0 | 178 |
2016 April | 152 | 0 | 152 |
2016 March | 125 | 0 | 125 |
2016 February | 170 | 0 | 170 |
2016 January | 124 | 0 | 124 |
2015 December | 158 | 0 | 158 |
2015 November | 137 | 0 | 137 |
2015 October | 108 | 0 | 108 |
2015 September | 73 | 0 | 73 |
2015 August | 106 | 0 | 106 |
2015 July | 126 | 0 | 126 |
2015 June | 53 | 0 | 53 |
2015 May | 41 | 0 | 41 |
2015 April | 6 | 0 | 6 |